Five years ago, the company listed on the Bucharest stock exchange, marking the first such move on the private healthcare market.
“The two new companies, which we hope will soon enter MedLife group, Oncocard and NeoLife, are specialized in oncology. With them, we will probably reach turnover worth EUR340 million at the end of 2021, pro-forma, together with the late-year acquisitions,” explained Mihai Marcu, MedLife chairman and CEO.
MedLife’s consolidation list in 2021 included Cluj-Napoca, Timisoara, Constanta, and the company’s investment budget for 2022 stands at EUR50-70 million just for deals.
(English version by Catalina Apostoiu)